2021-10-22
Akeso, Inc. Doses First Patient in a Clinical Study of Anti-TIGIT Monoclonal Antibody (AK127) in Combination with Cadonilimab (Anti-PD-1/CTLA-4) for Treatment of Advanced or Metastatic Solid Tumors
2021-10-18
Akeso Will Publish Six Latest Research Results at the SITC 2021
2021-10-12
Rapid Advancement of Phase II Clinical Trial of IL-4R Monoclonal Antibody (AK120) for the Treatment of Atopic Dermatitis and Asthma
2021-10-11
AK112 (PD-1/VEGF Bi-Specific Antibody) in Combination with AK117 (CD47 Monoclonal Antibody) Obtained Approval to Initiate Clinical Trial for the Treatment of Advanced Malignant Tumors
2021-10-05
PD-1/VEGF Bi-Specific Antibody (AK112) Obtained Approval to Initiate Clinical Trial for the Treatment of Advanced Triple-Negative Breast Cancer
2021-09-29
Completion of Patient Enrollment for Phase II Clinical Trial of IL-17A Monoclonal Antibody AK111 for Treatment of Moderate-to-Severe Plaque Psoriasis
2021-09-27
IL-4Rα Monoclonal Antibody (AK120) Initiates a Global Phase II Clinical Trial for the Treatment of Moderate-to-Severe Atopic Dermatitis
2021-09-26
Latest Results of a Phase II Clinical Study of PD-1/VEGF Bi-Specific Antibody (AK112) in Combination with Chemotherapy for First-Line Treatment of Advanced NSCLC Published at 2021 CSCO
2021-09-26
Akeso was included in the “Chinese Antibody Drug Companies Innovation TOP 30” by “2020 Chinese Biopharma Companies Innovation TOP 100 Series Lists”
2021-09-24
New Drug Application for Cadonilimab (PD-1/CTLA-4 Bi-Specific Antibody) for the Treatment of Relapsed or Metastatic Cervical Cancer Accepted by NMPA
2021-09-23
2021 CSCO | Latest Results of Two Phase II Clinical Studies of Akeso’s PD-1/VEGF Bispecific Antibody (AK112) for Treatment of Lung Cancer and Ovarian Cancer
2021-09-19
Akeso Publishes Updated Results of a Phase II Study of Penpulimab Monoclonal Antibody for Treatment of Metastatic NPC with Progression after Two or More Lines of Chemotherapy at ESMO 2021
2021-09-19
Akeso’s Latest Updates of a Phase Ib/II Trial of AK104 (PD-1/CTLA-4 Bi-Specific Antibody) in Combination with Anlotinib in Patients with PD-L1 Positive and Anti-PD-1/L1 Resistant Advanced NSCLC at ESMO 2021
2021-09-19
Oral Presentation of Mechanism Study of IgG1 Isotype Anti-PD-1 Monoclonal Antibody Penpulimab at ESMO 2021 by Akeso’s CSO, Dr. Baiyong Li
2021-08-27
Akeso, Inc. Works with Pfizer to Conduct a Clinical Research of Cadonilimab (Bi-specific Antibody) with Combination of Axitinib for the First-line Treatment of Advanced / Metastatic Renal Clear Cell Carcinoma
2021-08-24
Akeso’s PD-1/CTLA-4 Bi-Specific Antibody Obtained Approval from the CDE to Submit NDA and has been Granted Priority Review Designation
2021-08-23
New PD-1 Monoclonal Antibody 安尼可® (Penpulimab) Officially for Sale, First Prescriptions Made Nationwide
2021-08-21
Akeso Shipped off its First Batch of Penpulimab Monoclonal Antibody Injection (安尼可®)
2021-08-09
Akeso’s Latest Updates on the Clinical Trials of Cadonilimab and 安尼可 ® (Penpulimab) will be Published at ESMO 2021
2021-08-05
Penpulimab Monoclonal Antibody (PD-1) Obtains Marketing Approval in China
2021-08-05
New Drug Application for Penpulimab Monoclonal Antibody (PD-1) for Third-Line Treatment of Metastatic Nasopharyngeal Carcinoma Accepted by NMPA
2021-08-04
PD-1/CTLA-4 Bi-specific Antibody in Combination with VEGFR-2 Monoclonal Antibody Obtained Approval to Initiate Phase Ib/II Clinical Trial for Treatment of Advanced Solid Tumors
2021-08-03
Cadonilimab (PD-1/CTLA-4 Bispecific Antibody) Initiated Phase III Clinical Trial for First-Line Treatment of Advanced Gastric Cancer, National Researchers’ Conference Successfully Held
2021-07-13
CD47 Monoclonal Antibody (AK117) Completed Phase I Dose Escalation Trial and Obtained Approval to Initiate Clinical Trial in Combination with Azacitidine for Treatment of Acute Myeloid Leukemia
2021-07-09
Michael Xi: Anti-PD-1 bi-specific antibodies mark the immuno-oncology era 2.0
2021-07-06
Completed Patient Enrollment of the First Cohort with PD-1/CTLA-4 Bispecific Antibody (AK104) in Combination with CD47 Monoclonal Antibody (AK117) for Treatment of Solid Tumors
2021-07-05
Cadonilimab (PD-1/CTLA-4 Bispecific Antibody) in Combination with VEGFR-2 Monoclonal Antibody Obtained Approval to Initiate Phase Ib/II Clinical Trial for Treatment of Advanced Gastric Adenocarcinoma or Gastroesophageal Junction Cancer
2021-07-02
New Drug Application for Penpulimab Monoclonal Antibody (PD-1) for First-Line Treatment of Squamous Non-Small-Cell Lung Cancer Accepted by NMPA
2021-06-30
Akeso Awarded as 2021 "Most Honored Company" by Institutional Investor
2021-06-21
Akeso among “TOP 10 Chinese Bispecific Antibody Drug Companies” Ranked by BioChina List of China Biopharmaceuticals
2021-06-18
Akeso Dr. Xia Yu and Dr. Wang Zhongmin Win the First “World-Benefiting Pharmaceutical Innovation” Award
2021-06-16
Out-Licensed by Akeso to MSD for US$200 Million, Monoclonal Antibody CTLA-4 Entered Phase III Clinical Trial
2021-06-15
ASCO21 | Latest Updates on Two Akeso’s AK104 (PD-1/CTLA-4 Bispecific Antibody) Clinical Trials
2021-06-11
Akeso Expands Development with New International Center Project Settles in Shanghai
2021-05-24
Akeso Penpulimab Monoclonal Antibody (PD-1) Submitted BLA in the United States
2021-05-20
Latest Updates on the Clinical Trials of AK104, AK112, AK117 and AK105 Published at ASCO 2021
2021-05-18
CD47 Monoclonal Antibody (AK117) Obtained Approval for Phase I/II Clinical Trial for Treatment of Medium- to High-Risk Myelodysplastic Syndromes (MDS)
2021-05-13
Akeso, Inc. Inclusion in the MSCI China Index
2021-05-12
Initiation of Various Clinical Trials of PD-1/VEGF Bispecific Antibody (AK112)
2021-04-28
Cadonilimab (PD-1/CTLA-4 Bispecific Antibody) Obtained Approval to Initiate Phase III Clinical Trial for First-Line Treatment of Advanced Cervical Cancer
2021-04-27
New Level of Production Capacity Expansion Akeso Builds the World’s Largest FlexFactory Platform in Cooperation with Cytiva
2021-03-30
Penpulimab (PD-1) Obtained Breakthrough Therapy Designation from FDA for Third-Line Treatment of Metastatic Nasopharyngeal Carcinoma
2021-03-12
Akeso Guangzhou Manufacturing Base Project Phase I Goes into Operation
2021-03-03
Cadonilimab (PD-1/CTLA-4 Bispecific Antibody) Obtained Orphan Drug Designation from FDA of the United States for Treating Cervical Cancer
2020-07-30
Akeso, Inc. Promotes the Deployment of Innovative Pipeline Global Cooperation Appoints Dr. Michael (Chen) Chen as Business Development Vice President
2020-07-03
康方生物董事长兼首席执行官夏瑜女士入选2020福布斯“中国科技女性榜”
2020-05-25
Akesobio Announced NMPA Accepts its new drug Penpulimab (PD-1 Monoclonal Antibody) for the Treatment of relapsed or refractory Classic Hodgkin's Lymphoma
2020-05-11
Akesobio Doses First Patient in Phase 1 Study of AK117, a novel anti-CD47 monoclonal antibody in Australia
2020-04-02
AACR 2020 | Akesobio presents phase Ib/II preliminary results of AK104, a PD-1/CTLA-4 bispecific antibody in combination with chemotherapy as first-line therapy in patients (pts) with advanced gastric (G) or gastroesophageal junction (GEJ) cancer